# Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy

> **NCT05828238** · EARLY_PHASE1 · UNKNOWN · sponsor: **Affiliated Hospital of Jiangnan University** · enrollment: 10 (estimated)

## Conditions studied

- Breast Cancer Stage II
- Breast Cancer Stage III
- Solid Tumor

## Interventions

- **DRUG:** [18F]SF-DEVD-2
- **DRUG:** [18F]-FDG

## Key facts

- **NCT ID:** NCT05828238
- **Lead sponsor:** Affiliated Hospital of Jiangnan University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01
- **Primary completion:** 2024-01
- **Final completion:** 2024-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05828238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05828238, "Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05828238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*